8 rows where subject contains "Obstetrics and Gynaecology"

View and edit SQL

Suggested facets: subject, references-count, is-referenced-by-count, ISSN, container-title, author_number, orcids, award_numbers, funder_names, funder_dois, created (date), title (array), ISSN (array), orcids (array), names (array), award_numbers (array), funder_names (array), funder_dois (array)

subject (array)

Link rowid ▼ title DOI URL created subject references-count is-referenced-by-count ISSN container-title abstract author_number orcids names award_numbers funder_names funder_dois
10 ["Prognostic Impact of Parity in 493 Uterine Sarcoma Patients"] 10.1111/igc.0b013e3181aaa950 http://dx.doi.org/10.1111/igc.0b013e3181aaa950 2010-12-03T18:36:56Z ["Obstetrics and Gynaecology", "Oncology"] 28 11 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Introduction:</jats:title><jats:p>Nulliparity has been found to negatively affect prognosis among endometrial cancer patients. Few previous studies have examined the prognostic impact of parity in patients with uterine sarcomas.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>In the present nationwide, register-based study in Norway, we explore whether parity influences survival among 493 women diagnosed with malignant uterine sarcomas. Hazard ratios for total mortality were calculated in Cox proportional hazard regression analyses.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The 5-year Kaplan-Meier survival rates for the 126 endometrial stromal sarcoma (ESS) patients, 249 leiomyosarcoma (LS) patients, and 118 carcinosarcoma (CS) patients were 74%, 68%, and 55%, respectively, but varied considerably by age at diagnosis and clinical stage. In the univariate analyses, nulliparous women had poorer prognosis than parous women among CS patients (<jats:italic>P</jats:italic> = 0.071, log-rank test) and ESS patients (<jats:italic>P</jats:italic> = 0.15). In analyses adjusted for clinical stage and age at diagnosis, nulliparity was associated with a worse outcome in ESS patients only (hazard ratio, 0.50; 95% confidence interval, 0.22-1.12; parous vs nulliparous women); a trend with increasing number of births was also observed, of borderline significance (<jats:italic>P</jats:italic> = 0.058). No independent prognostic impact of parity was found in LS or CS patients. However, a considerably higher proportion of nulliparous than parous CS patients was diagnosed with advanced-stage disease (<jats:italic>P</jats:italic> = 0.003).</jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p>Nulliparity seems to be associated with poorer prognosis in ESS patients; no independent prognostic impact of parity was seen among LS or CS patients. Further knowledge on underlying biological mechanisms may be valuable for improved treatment.</jats:p></jat… 4 [] ["Grethe Albrektsen", "Ivar Heuch", "Elisabeth Wik", "Helga B. Salvesen"] [""] [""] [""]
29 ["Ovarian fibrosarcoma with long-term survival: A case report"] 10.1136/ijgc-00009577-200107000-00016 http://dx.doi.org/10.1136/ijgc-00009577-200107000-00016 2019-03-05T12:15:23Z ["Obstetrics and Gynaecology", "Oncology"] 0 3 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Abstract.</jats:title><jats:p>Huang Y-C, Hsu K-F, Chou C-Y, Dai Y-C, Tzeng C-C. Ovarian fibrosarcoma with long-term survival.</jats:p><jats:p>Primary ovarian fibrosarcoma is an exceedingly rare malignant ovarian stromal tumor which has a poor prognosis. We report here a 46-year-old woman who suffered from irregular vaginal bleeding for 2 months. She received hysterectomy and salpingo-oophorectomy due to a provisional diagnosis of uterine and ovarian tumors. At surgery, an 8-cm ovarian solid multilobular tumor was found. Frozen section examination revealed an ovarian fibrosarcoma. She then underwent staging procedures including intraperitoneal washing, cytology, and pelvic and para-aortic lymph node sampling. Final pathologic examination revealed that the tumor exhibited densely packed spindle cells in storiform configuration with obvious increased mitotic activity. In addition, the flow cytometric study showed marked elevated percentage of tumor cells in the S phase (13.1%). After surgery, the patient received six courses of combination chemotherapy with epirubicin, ifosfamide, and dacarbazine (DTIC). The patient stood the treatment well and is free from disease 6 years later.</jats:p></jats:sec> 5 [] ["Y.-C. Huang", "K.-F. Hsu", "C.-Y. Chou", "Y.-C. Dai", "C.-C. Tzeng"] [""] [""] [""]
38 ["A case of protrusion of an intraperitoneal chemotherapy catheter through rectum"] 10.1136/ijgc-00009577-200501000-00026 http://dx.doi.org/10.1136/ijgc-00009577-200501000-00026 2019-03-06T16:30:38Z ["Obstetrics and Gynaecology", "Oncology"] 0 1 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:p>Bowel penetration of an intraperitoneal catheter occurred in a patient who had received a course of uncomplicated intraperitoneal chemotherapy for a persistent ovarian carcinoma. One month after the termination of chemotherapy, she presented with protrusion of a catheter through anus. At operation, the catheter was removed, the rectum was repaired primarily, and a cytoreductive surgery was performed.</jats:p> 5 [] ["Y. Bilsel", "E. Balik", "D. Bugra", "S. Yamaner", "A. Akyuz"] [""] [""] [""]
60 ["Successful use of anti-retroviral therapy in combination with cytotoxic chemotherapy for persistent molar pregnancy: A case report"] 10.1136/ijgc-00009577-200303000-00026 http://dx.doi.org/10.1136/ijgc-00009577-200303000-00026 2019-03-06T09:50:37Z ["Obstetrics and Gynaecology", "Oncology"] 0 0 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:p>Due to the HIV pandemic, the chances of finding gynecological malignancies in HIV-infected women are increased. This poses management and ethical dilemmas as the treatment for such malignancies are likely to further decrease their immunity. Gestational trophoblastic disease occurs predominantly among young women and has excellent response to chemotherapy. However, such therapy is not possible if their immunity (CD<jats:sub>4</jats:sub> counts) is markedly depressed. The patient described presented with persistent molar pregnancy and had low CD<jats:sub>4</jats:sub> count. She was given antiretroviral therapy and once the CD<jats:sub>4</jats:sub> count had risen to acceptable levels cytotoxic chemotherapy was administered. She received a total of 13 cycles of chemotherapy with no significant untoward effects. After a 6-month follow-up period the patient was well with a negative serum βHCG level and CD<jats:sub>4</jats:sub> count above 200. We conclude that HIV-infected women with gestational trophoblastic disease may be safely treated with cytotoxic chemotherapy provided anti-retroviral therapy is concurrently administered to boost immunity.</jats:p> 2 [] ["M. Moodley", "J. Moodley"] [""] [""] [""]
62 ["The Selection of Time Interval Between Surgery and Adjuvant Therapy in Early Stage Cervical Cancer"] 10.1097/igc.0000000000001307 http://dx.doi.org/10.1097/igc.0000000000001307 2018-08-02T22:02:59Z ["Obstetrics and Gynaecology", "Oncology"] 21 0 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Objectives</jats:title><jats:p>The optimal interval between surgery and adjuvant treatment has not yet been found in cervical cancer. And whether patients with different FIGO stage should choose different interval is unknown. The purpose of this study was to evaluate whether interval has a different effect on oncologic outcome for patients with different tumor stages.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a retrospective study of 226 cervical cancer patients who were treated by surgery and adjuvant therapy from May 2005 to August 2015. All patients were divided into 2 groups according to the interval of 5 weeks. Overall survival (OS) and disease-free survival (DFS) were compared between patients with interval shorter and longer than 5 weeks in the whole group and subgroups. Recurrence patterns were also analyzed. Multivariate analysis was performed to explore clinical factors significantly associated with DFS, local recurrence-free survival and distant metastasis-free survival for patients with stage IB2–IIA.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>For patients with stage IA2–IB1, the 5-year OS and DFS were similar between groups of short and long interval with also the comparable results of local and distant failure. For patients with IB2–IIA, both the OS and DFS in the short-interval group were higher than that in the long-interval group. Besides, the rates of local recurrence were found higher in the group of long interval compared with short interval. Multivariable analysis indicated that time interval was an independent predictor of DFS and local recurrence-free survival for patients with stage IB2–IIA.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In cervical cancer patients, time interval between surgery and adjuvant therapy may have different effects on the prognosis in different FIGO stages.</jats:p></jats:sec> 6 [] ["Kai-Yun You", "Xin-Hui Zhou", "Yan-Hui Jiang", "Zhuo-Fei Bi", "Yi-Min Liu", "Xing-Sheng Qiu"] [""] [""] [""]
69 ["Cell therapy for the preterm infant: promise and practicalities"] 10.1136/archdischild-2019-317896 http://dx.doi.org/10.1136/archdischild-2019-317896 2020-04-06T21:15:32Z ["Obstetrics and Gynaecology", "Pediatrics, Perinatology, and Child Health", "General Medicine"] 0 0 ["1359-2998", "1468-2052"] Archives of Disease in Childhood - Fetal and Neonatal Edition <jats:p>Recent decades have seen the rapid progress of neonatal intensive care, and the survival rates of the most preterm infants are improving. This improvement is associated with changing patterns of morbidity and new phenotypes of bronchopulmonary dysplasia and preterm brain injury are recognised. Inflammation and immaturity are known contributors to their pathogenesis. However, a new phenomenon, the exhaustion of progenitor cells is emerging as an important factor. Current therapeutic approaches do not adequately address these new mechanisms of injury. Cell therapy, that is the use of stem and stem-like cells, with its potential to both repair and prevent injury, offers a new approach to these challenging conditions. This review will examine the rationale for cell therapy in the extremely preterm infant, the preclinical and early clinical evidence to support its use in bronchopulmonary dysplasia and preterm brain injury. Finally, it will address the challenges in translating cell therapy from the laboratory to early clinical trials.</jats:p> 5 ["http://orcid.org/0000-0001-6742-7314"] ["Elizabeth K Baker", "Susan E Jacobs", "Rebecca Lim", "Euan M Wallace", "Peter G Davis"] ["Research Training Program Scholarship"] ["University of Melbourne", "National Health and Medical Research Council"] ["10.13039/501100001782", "10.13039/501100000925"]
71 ["Phase III randomized pilot study comparing interferon \u03b1- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix"] 10.1136/ijgc-00009577-200303000-00011 http://dx.doi.org/10.1136/ijgc-00009577-200303000-00011 2019-03-06T14:50:37Z ["Obstetrics and Gynaecology", "Oncology"] 0 0 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:p>This randomized pilot study was designed to determine whether the addition of interferon α-2b to standard radiation therapy offered an advantage in loco-regional control and survival over radiation therapy alone in a homogeneous group of patients with stage IIIB carcinoma of the cervix. Thirty-six patients were treated with a combination of interferon α-2b plus radiation therapy, and 38 patients were treated with radiation therapy alone. Patients with evidence of ureteral obstruction were excluded from the study. Evaluation of loco-regional response was determined by pelvic examination, cervical cytology, biopsies and CT scans when indicated. Survival time was measured from initiation of treatment to date of death or last follow-up. Patient characteristics were comparable between both study arms. The objective complete response rate was 67% in the combined therapy group and 55% in the radiation alone group (<jats:italic>P</jats:italic> = 0.454). With a median follow-up of 17 months for all patients and 31 months for live patients, 50% of the combined group survived vs. 39.5% of the radiation alone group (<jats:italic>P</jats:italic> = 0.424). We conclude that the addition of interferon α-2b to standard radiation therapy did not significantly improve loco-regional response or survival, although such a trend was noted. We encourage the design of a larger randomized study with sufficient power to detect meaningful differences to prove whether the tendency observed in the present investigation holds any promise to improve the outcome of these patients.</jats:p> 14 [] ["R. Yazigi", "G. Aliste", "R. Torres", "A. M. Ciudad", "M. Cuevas", "J. Garrido", "S. Prado", "A. Sol\u00e1", "R. Castillo", "B. Cerda", "M. A. Cumsille", "M. Gonz\u00e1lez", "C. Navarro", "J. M. Reyes"] [""] [""] [""]
72 ["Diffuse excessive high signal intensity on term equivalent MRI does not predict disability: a systematic review and meta-analysis"] 10.1136/archdischild-2019-318207 http://dx.doi.org/10.1136/archdischild-2019-318207 2020-05-25T21:17:07Z ["Obstetrics and Gynaecology", "Pediatrics, Perinatology, and Child Health", "General Medicine"] 39 0 ["1359-2998", "1468-2052"] Archives of Disease in Childhood - Fetal and Neonatal Edition <jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate whether diffuse excessive high signal intensity (DEHSI) on term equivalent age MRI (TEA-MRI) predicts disability in preterm infants.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>This is a systematic review and meta-analysis. Medline, EMBASE, Cochrane Library, EMCARE, Google Scholar and MedNar databases were searched in July 2019. Studies comparing developmental outcomes of isolated DEHSI on TEA-MRI versus normal TEA-MRI were included. Two reviewers independently extracted data and assessed the risk of bias. Meta-analysis was undertaken where data were available in a format suitable for pooling.</jats:p></jats:sec><jats:sec><jats:title>Main outcome measures</jats:title><jats:p>Neurodevelopmental outcomes ≥1 year of corrected age based on validated tools.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 15 studies (n=1832) were included, of which data from 9 studies were available for meta-analysis. The pooled estimate (n=7) for sensitivity of DEHSI in predicting cognitive/mental disability was 0.58 (95% CI 0.34 to 0.79) and for specificity was 0.46 (95% CI 0.20 to 0.74). The summary area under the receiver operating characteristics (ROC) curve was low at 0.54 (CI 0.50 to 0.58). A pooled diagnostic OR (DOR) of 1 indicated that DEHSI does not discriminate preterm infants with and without mental disability. The pooled estimate (n=8) for sensitivity of DEHSI in predicting cerebral palsy (CP) was 0.57 (95% CI 0.37 to 0.75) and for specificity was 0.41 (95% CI 0.24 to 0.62). The summary area under the ROC curve was low at 0.51 (CI 0.46 to 0.55). A pooled DOR of 1 indicated that DEHSI does not discriminate between preterm infants with and without CP.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>DEHSI on TEA-MRI did not predict future development of cognitive/mental disabilities or CP.</jats:p></jats:sec><jats:sec><jats:title>PROSPERO registration number</jats:title><jats:p>CRD4… 4 [] ["Chandra Prakash Rath", "Saumil Desai", "Shripada C Rao", "Sanjay Patole"] [""] [""] [""]

Advanced export

JSON shape: default, array, newline-delimited

CSV options:

CREATE TABLE [article] (
   [title] TEXT,
   [DOI] TEXT,
   [URL] TEXT,
   [created] TEXT,
   [subject] TEXT,
   [references-count] TEXT,
   [is-referenced-by-count] TEXT,
   [container-title] TEXT,
   [abstract] TEXT,
   [author_number] TEXT,
   [orcids] TEXT,
   [names] TEXT,
   [award_numbers] TEXT,
   [funder_names] TEXT,
   [funder_dois] TEXT